Barclays Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Stock analysts at Barclays started coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report issued on Friday,Benzinga reports. The brokerage set an “overweight” rating and a $923.00 price target on the biopharmaceutical company’s stock. Barclays‘s price target suggests a potential upside of 20.66% from the company’s previous close.

Other research analysts have also issued reports about the company. Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Stock Down 2.9%

Shares of REGN stock opened at $764.93 on Friday. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The stock has a market cap of $80.87 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 2.12 and a beta of 0.41. The firm’s 50-day moving average is $771.31 and its 200-day moving average is $686.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the company posted $12.07 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 in the last three months. 7.02% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Insigneo Advisory Services LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 13 shares during the period. Guardian Wealth Advisors LLC NC increased its position in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC raised its stake in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares in the last quarter. MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Finally, Rexford Capital Inc. lifted its position in Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.